2C-T-2

Pre-existing hypertension, coronary artery disease, arrhythmias, or heart failure increase risk of cardiovascular adverse events. 2C drug intoxication characteristically presents with tachycardia and hypertension.

History of epilepsy or seizure disorders increases risk. Seizures are documented in 2C drug class clinical presentations.

Personal or family history of schizophrenia, schizoaffective disorder, or other psychotic disorders is an absolute contraindication for all serotonergic psychedelics including 2C-T-2.

Bipolar disorder (types I and II) increases risk of manic episode precipitation. Risk may be modified by mood stabilizer status, but lithium co-administration is separately contraindicated.

Pregnancy is an absolute contraindication. No safety data exist for 2C-T-2 during pregnancy or breastfeeding.

phenelzine therapy, tranylcypromine therapy, selegiline therapy, moclobemide therapy, harmine/harmaline use

Concurrent use of any MAO inhibitor — irreversible (phenelzine, tranylcypromine), reversible (moclobemide), MAO-B selective (selegiline at higher doses), or botanical (harmine/harmaline in ayahuasca) — is absolutely contraindicated. This is a pharmacokinetically-mediated interaction established by Theobald & Maurer 2007.

Concurrent lithium therapy is an absolute contraindication. Community reports consistently describe severe adverse reactions when lithium is combined with serotonergic psychedelics, including seizures and prolonged psychotic episodes.